(-0.14%) 5 139.75 points
(-0.02%) 38 553 points
(-0.16%) 17 876 points
(0.16%) $82.76
(2.07%) $2.07
(-1.28%) $2 327.50
(-2.64%) $26.93
(-1.32%) $948.80
(-0.06%) $0.932
(0.25%) $11.01
(0.08%) $0.797
(-0.07%) $93.24
0.53% ¥ 1 514.00
Live Chart Being Loaded With Signals
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant...
Stats | |
---|---|
Dagens volum | 10.25M |
Gjennomsnittsvolum | 9.29M |
Markedsverdi | 2 714.75B |
EPS | ¥0 ( 2024-04-25 ) |
Last Dividend | ¥30.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 558.67 |
ATR14 | ¥0.662 (0.04%) |
Volum Korrelasjon
Astellas Pharma Inc. Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Astellas Pharma Inc. Korrelasjon - Valuta/Råvare
Astellas Pharma Inc. Økonomi
Annual | 2023 |
Omsetning: | ¥1 603.67B |
Bruttogevinst: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2023 |
Omsetning: | ¥1 603.67B |
Bruttogevinst: | ¥1 212.37B (75.60 %) |
EPS: | ¥9.50 |
FY | 2022 |
Omsetning: | ¥1 518.62B |
Bruttogevinst: | ¥1 230.27B (81.01 %) |
EPS: | ¥54.24 |
FY | 2022 |
Omsetning: | ¥1 296.16B |
Bruttogevinst: | ¥1 043.15B (80.48 %) |
EPS: | ¥67.08 |
Financial Reports:
No articles found.
Astellas Pharma Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥30.00 (N/A) |
¥0 (N/A) |
¥30.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥3.00 | 2000-03-28 |
Last Dividend | ¥30.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 48 | -- |
Total Paid Out | ¥591.00 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.71 | -- |
Div. Sustainability Score | 8.06 | |
Div.Growth Potential Score | 6.81 | |
Div. Directional Score | 7.43 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
4912.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
4072.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
3288.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
2335.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
9856.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
8914.T | Ex Dividend Junior | 2023-12-28 | Annually | 0 | 0.00% | |
8020.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
7270.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
6505.T | Ex Dividend Junior | 2024-05-30 | Annually | 0 | 0.00% | |
5715.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00805 | 1.500 | 9.84 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00362 | 1.200 | 9.88 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00817 | 1.500 | -1.020 | -1.530 | [0.1 - 1] |
payoutRatioTTM | 9.04 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.929 | 0.800 | -0.354 | -0.283 | [1 - 3] |
quickRatioTTM | 0.687 | 0.800 | -0.663 | -0.530 | [0.8 - 2.5] |
cashRatioTTM | 0.261 | 1.500 | 9.66 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.258 | -1.500 | 5.70 | -8.56 | [0 - 0.6] |
interestCoverageTTM | 8.97 | 1.000 | 7.79 | 7.79 | [3 - 30] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.576 | -1.500 | 7.69 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.797 | 1.000 | 0.0457 | 0.0457 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0672 | 1.000 | -0.657 | -0.657 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.190 | 1.000 | -0.0541 | -0.0541 | [0.2 - 2] |
assetTurnoverTTM | 0.449 | 0.800 | -0.338 | -0.271 | [0.5 - 2] |
Total Score | 8.06 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 210.39 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00817 | 2.50 | -0.656 | -1.530 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 51.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.62 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 97.61 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 9.04 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 63.54 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.109 | 1.000 | 9.77 | 0 | [0.1 - 0.5] |
Total Score | 6.81 |
Astellas Pharma Inc.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. It provides XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation-positive; PADCEV, a treatment solution for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of urgency, urinary frequency, and urge urinary incontinence; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, which are immunosuppressants used to suppress organ rejection following a transplant. The company also offers mirabegron for the treatment of neurogenic detrusor overactivity in pediatric patients; Vesicare for OAB treatment; Eligard to treat prostate cancer; Harnal/Omnic for benign prostatic hyperplasia treatment; and Funguard/MYCAMINE, an antifungal agent. The company has a clinical trial collaboration with Merck & Co., Inc.; CytomX Therapeutics, Inc.; and an agreement with BANDAI NAMCO Entertainment Inc. for the development of smartphone exercise support application. It also has strategic research alliance with Harvard University for the research and development of therapeutics and technologies of mutual interest; research collaboration with Actinium Pharmaceuticals, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platform, as well as agreement with Zenith Epigenetics Ltd. to evaluate ZEN-3694; and collaboration agreement with Cytokinetics, Incorporated. The company has a strategic collaboration and license agreement with Minovia Therapeutics Ltd. for the research, development, and commercialization of cell therapy programs for diseases caused by mitochondrial dysfunction. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.